Aurora Cannabis Inc. (TSE:ACB) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$12.20

By
Simply Wall St
Published
November 11, 2020
TSX:ACB

The investors in Aurora Cannabis Inc.'s (TSE:ACB) will be rubbing their hands together with glee today, after the share price leapt 85% to CA$10.78 in the week following its first-quarter results. The results don't look great, especially considering that statutory losses grew 111% toCA$0.92 per share. Revenues of CA$68m did beat expectations by 6.4%, but it looks like a bit of a cold comfort. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for Aurora Cannabis

earnings-and-revenue-growth
TSX:ACB Earnings and Revenue Growth November 11th 2020

Taking into account the latest results, the consensus forecast from Aurora Cannabis' 15 analysts is for revenues of CA$309.4m in 2021, which would reflect a meaningful 13% improvement in sales compared to the last 12 months. Losses are predicted to fall substantially, shrinking 97% to CA$1.17. Before this earnings announcement, the analysts had been modelling revenues of CA$313.9m and losses of CA$1.15 per share in 2021.

The consensus price target rose 6.9% to CA$12.20, with the analysts increasing their valuations as the business executes in line with forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Aurora Cannabis at CA$33.00 per share, while the most bearish prices it at CA$3.60. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Aurora Cannabis' revenue growth is expected to slow, with forecast 13% increase next year well below the historical 66%p.a. growth over the last three years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 31% next year. Factoring in the forecast slowdown in growth, it seems obvious that Aurora Cannabis is also expected to grow slower than other industry participants.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply revenues will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that in mind, we wouldn't be too quick to come to a conclusion on Aurora Cannabis. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Aurora Cannabis going out to 2025, and you can see them free on our platform here..

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Aurora Cannabis (at least 1 which is a bit concerning) , and understanding them should be part of your investment process.

Promoted
If you’re looking to trade Aurora Cannabis, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.


This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.


Simply Wall St character - Warren

Simply Wall St

Simply Wall St is a financial technology startup focused on providing unbiased, high-quality research coverage on every listed company in the world. Our research team consists of equity analysts with a public, market-beating track record. Learn more about the team behind Simply Wall St.